Director Kennedy Lawrence T. Jr bought 35,000 shares of BDSX at $1.16 on 2024-11-21; stock down 39.6% from 52-week high.
Kennedy Lawrence T. Jr., a director holding 10.41M shares post-transaction, purchased 35,000 shares at $1.16 on 2024-11-21, representing a $40.6K outlay. This is his third open-market buy across all tickers; at BDSX specifically, he also bought on 2024-11-05 and 2024-11-06, indicating repeated accumulation within a 16-day window. The stock has declined 39.6% from its 52-week high and fallen 19.0% over the past 30 days, placing the purchase price substantially below recent market levels. BDSX is unprofitable on a full-year basis with net income of $-10.3M against quarterly revenue of $18.2M, though annual revenue growth reached 28.5%. The director's concentrated position (10.41M shares represents substantial ownership) and sequential purchases at depressed price levels warrant monitoring to understand whether the pattern reflects conviction in recovery or other strategic considerations.
Director Kennedy Lawrence T. Jr bought 71,200 shares in 2 tranches at $1.36 ($97,068 total); 4 other insiders also bought within 14 days
Kennedy Lawrence T. Jr, a director at BIODESIX INC, executed 2 purchases totaling 71,200 shares (71.2K shares) for $97,068.00 ($97.1K) on November 5-6, 2024, at a blended average price of $1.36 per share. This activity is notable because it occurs within a broader cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated activity among multiple executives. The company's fundamentals show material challenges: it generated $18.2M in quarterly revenue but posted a net loss of $-10.3M over its most recent full fiscal year, despite +28.5% annual revenue growth. The stock has declined 21.3% over the past 30 days and 37.3% from its 52-week high of $42.40, now trading at $26.60. The convergence of multiple insider purchases during a significant price decline warrants scrutiny of the circumstances driving these acquisitions.
